Scleroderma News

Inability to use one’s fingers and the appearance of new ulcers are among the top five concerns that would prompt treatment escalation in patients with Raynaud’s phenomenon secondary to systemic sclerosis, according to data.

Digital ulcers in patients with systemic sclerosis often need early assessment and systemic treatments, according to a review published in JAMA Dermatology.

Patients with systemic sclerosis demonstrate a four-fold increased prevalence of moderate-to-severe valvular heart disease at diagnosis compared with those without systemic sclerosis, according to data published in The Journal of Rheumatology.

Patients who received rheumatology care from nurse practitioners or physician assistants rated their overall experience similarly to those who saw a rheumatologist, according to survey data published in Arthritis Care & Research.

Although lenabasum failed to meet its efficacy endpoint in a trial of patients with diffuse cutaneous systemic sclerosis, a post-hoc analysis suggests an impact on forced vital capacity, according to a speaker at the EULAR 2021 Congress.

A questionnaire developed at the University of California, Los Angeles, can discriminate patients with systemic sclerosis who have an indication for esophago-gastro-duodenoscopy, according to data published in Arthritis Research & Therapy.

Early intervention is critical for patients who are likely to progress to serious complications from systemic sclerosis-associated interstitial lung disease, according to a presenter at the Biologic Therapies Summit.

A virtual group program aimed at providing mental health coping strategies and reducing isolation during COVID-19 lockdowns in patients with scleroderma failed to significantly improve anxiety post-intervention, according to data.

Microvascular complications from the use of calcitonin gene-related peptide antagonists for migraines are uncommon in patients with underlying Raynaud’s syndrome, according to data published in JAMA Network Open.

In the SENSCIS-ON trial, two-thirds of patients with systemic sclerosis-associated interstitial lung disease who continued nintedanib after completion of the SENSCIS trial maintained stable lung function or had improvement in lung function.